IGFBP-2 Vaccine + Carboplatin for Ovarian Cancer

This trial explores a new vaccine targeting a protein found in ovarian cancer cells. The vaccine, named pUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine, is administered after a dose of carboplatin, a chemotherapy drug, to determine if it can prevent the cancer from spreading or worsening in patients with recurrence signs in their blood tests after previous treatment. It is intended for those with ovarian, fallopian tube, or primary peritoneal cancer who have received platinum-based chemotherapy and now exhibit increasing cancer markers in their blood but no visible tumors. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.

The trial does not specify if you need to stop taking your current medications. However, you cannot participate if you are on systemic steroid therapy above a certain dose or if you have received certain treatments recently. It's best to discuss your specific medications with the trial team.

Research has shown that the IGFBP-2 vaccine is likely safe for patients. Previous studies focused on its safety and suggest that most patients tolerate it well.

Earlier research noted only mild side effects, such as redness at the injection site or slight tiredness, which are common and expected with vaccines. No serious side effects were directly linked to the vaccine.

Carboplatin, a chemotherapy drug used for many years, is well-understood and considered safe under a doctor's care.

Researchers are excited about the IGFBP-2 vaccine with carboplatin for ovarian cancer because it offers a novel approach compared to traditional chemotherapy. While standard treatments often rely on broad-acting chemotherapy drugs, this treatment uniquely combines carboplatin with a targeted vaccine that stimulates the immune system to recognize and attack cancer cells expressing the IGFBP-2 protein. This dual approach not only aims to enhance the effectiveness of carboplatin but also provides a more personalized treatment strategy, potentially leading to better outcomes and fewer side effects. The integration of a vaccine into ovarian cancer treatment is an innovative step that holds promise for improving patient responses and long-term survival rates.

In this trial, participants will receive a combination of the IGFBP-2 vaccine and carboplatin. Research suggests that the IGFBP-2 vaccine might help the immune system identify and destroy ovarian cancer cells, as IGFBP-2 is a protein often present in these cells, making it an easy target. Combining this vaccine with carboplatin, a chemotherapy drug that can also enhance the immune system, may increase treatment effectiveness. Studies with previous patients have shown that this combination might help prevent cancer from returning or worsening. Although still under investigation, early results indicate that this method could be promising for treating ovarian cancer.¹²⁵⁶⁷